Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022

Enrollment completed and dosing resumed in the ongoing Phase 2 REVIVE study Resumption of rusfertide administration after suspension restored therapeutic benefits including hematocrit control, reduced red blood cell count, and decreased phlebotomy rate NEWARK, Calif., May 26, 2022...

Click to view original post